Calcium signaling plays a central role in regulating cancer cell survival, programmed cell death, and responses to anticancer treatment

 Highlights

• Intracellular calcium acts as a universal signaling molecule in living cells
• Calcium signaling regulates cell proliferation, gene expression, and programmed cell death
• Disrupted calcium homeostasis may contribute to cancer progression and treatment resistance
• Several anticancer drugs alter intracellular calcium through different biological mechanisms
• Targeting calcium-dependent pathways may support future combination treatment strategies

Summary

Calcium is widely recognized for its structural role in bones and teeth, but inside living cells it also functions as a highly regulated signaling molecule.

Changes in intracellular calcium concentration help control essential cellular processes, including cell proliferation, gene expression, metabolism, communication between cellular compartments, and programmed cell death.

This scientific review examined the role of intracellular calcium signaling in cancer biology and cancer treatment. Cancer cells often develop abnormalities in the pathways that normally trigger apoptosis, allowing damaged or abnormal cells to survive and continue multiplying.

Because calcium signals are involved in both the initiation and execution of apoptosis, researchers have increasingly investigated calcium-regulating pathways as potential therapeutic targets.

The review discusses several anticancer drugs known to affect intracellular calcium homeostasis, including cisplatin, carboplatin, topotecan, and arsenic trioxide.

These treatments may increase intracellular calcium through several mechanisms. Calcium may enter the cell from the extracellular environment, be released from internal storage sites such as the endoplasmic reticulum, or accumulate when calcium transport systems are inhibited.

The authors focused particularly on research involving cisplatin and arsenic trioxide. Although both compounds altered intracellular calcium levels, they appeared to act through different pathways.

Arsenic trioxide primarily stimulated calcium release from intracellular stores, while cisplatin promoted calcium entry from outside the cell. Sustained increases in intracellular calcium were associated with greater cytotoxicity and apoptosis in neuroblastoma cells.

When the two compounds were applied together under laboratory conditions, they produced additive or potentially synergistic effects on calcium homeostasis. The strongest response occurred when cells were first exposed to cisplatin and then treated with both compounds.

These observations suggest that understanding how different therapies influence calcium signaling may help researchers develop more effective combination approaches and better understand mechanisms of treatment resistance.

Why This Matters

From a systems biology perspective, calcium signaling is a fundamental regulatory process that extends far beyond skeletal health.

The review supports the concept that:

• Calcium functions as a universal intracellular messenger
• Cellular survival depends on tightly controlled calcium homeostasis
• Abnormal calcium signaling may allow cancer cells to avoid programmed cell death
• Changes in calcium transport and storage may contribute to drug resistance
• Different treatments may influence calcium signaling through distinct cellular pathways

Drug resistance remains one of the greatest challenges in cancer treatment. The review describes evidence that drug-resistant cancer cells may develop changes in calcium entry, calcium storage, and the systems responsible for restoring normal intracellular calcium levels.

This suggests that treatment resistance may involve more than a drug failing to reach its intended target. Cancer cells may also adapt by modifying the signaling systems that regulate survival and apoptosis.

Studying calcium-dependent pathways may therefore help researchers understand why certain cancer cells survive treatment and how different therapies might be combined to overcome those adaptations.

Conclusion

This review highlights intracellular calcium signaling as an important area of cancer biology and therapeutic research.

Calcium signals help regulate cell proliferation, programmed cell death, and responses to anticancer drugs. Disruption of these signals may also contribute to cancer progression and treatment resistance.

The publication does not evaluate a calcium supplement, nutritional product, or SAC formulation. Instead, it provides a broader scientific framework for understanding how tightly regulated intracellular calcium signaling influences cellular behavior.

Further research is needed to identify the specific calcium channels, receptors, transporters, and intracellular pathways that may become future therapeutic targets.